PTEN-5-HT2C coupling: a new target for treating drug addiction

Progress in Brain Research

Volumn 172, Issue , 2008, Pages 407-420

  Maillet, Jean Christian ^a   Zhang, Yun ^a   Li, Xuesheng ^a   Zhang, Xia ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

5 HT2C receptor; cannabinoids; coupled receptors; drug addiction; G protein; PTEN; Tat 3L4F; ventral tegmental area

Indexed keywords

2 (6 CHLORO 5 FLUORO 1 INDOLYL) 1 METHYLETHYLAMINE; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 6 CHLORO 5 METHYL 1 [[2 [(2 METHYL 3 PYRIDYL)OXY] 5 PYRIDYL]CARBAMOYL]INDOLINE; DEXANABINOL; DRONABINOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PEPTIDE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; SEROTONIN 2C RECEPTOR; SMALL INTERFERING RNA; TAT 3L4F PEPTIDE; UNCLASSIFIED DRUG;

BEHAVIORAL SCIENCE; DOPAMINERGIC NERVE CELL; DRUG ABUSE; DRUG DEPENDENCE; DRUG TARGETING; IMMUNOPRECIPITATION; INHIBITORY POSTSYNAPTIC POTENTIAL; LONG TERM DEPRESSION; MAZE TEST; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; SPATIAL MEMORY; VENTRAL TEGMENTUM;

ANIMALS; BEHAVIOR, ANIMAL; DOPAMINE; HUMANS; NEURONS; PEPTIDES; PTEN PHOSPHOHYDROLASE; RECEPTOR, SEROTONIN, 5-HT2C; REWARD; SEROTONIN; SEROTONIN AGONISTS; STREET DRUGS; SUBSTANCE-RELATED DISORDERS; VENTRAL TEGMENTAL AREA;

EID: 50349100359     PISSN: 00796123     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0079-6123(08)00920-5     Document Type: Review

References (62)

1. Alberts G.L., Pregenzer J.F., Im W.B., Zaworski P.G., and Gill G.S. Agonist induced GTPγ35S binding mediated by human 5-HT2c receptors expressed in human embryonic kidney 293 cells. Eur. J. Pharmacol. 383 3 (1999) 311-319
2. Alves S.H., Pinheiro G., Motta V., landeira-Fernandez J., and Cruz A.P. Anxiogenic effects in the rat elevated plus-maze of 5-HT(2C) agonists into ventral but no dorsal hippocampus. Behav. Pharmacol. 15 1 (2004) 37-43
3. Backstrom J.R., Price R.D., Reasoner D.T., and Sanders-Bush E. Deletion of the serotonin 5-HT2c receptor PDZ recognition motif prevents receptor phosphorylation and delays resensitization of receptor responses. J. Biol. Chem. 275 31 (2000) 23620-23626
4. Berg K.A., Maayani S., Goldfarb J., and Clarke W.P. Pleiotropic behavior of 5-HT2A and 5-HT2C receptor agonists. Ann. NY. Acad. Sci. 861 (1998) 104-110
5. Bubar M.J., and Cunningham K.A. Distribution of serotonin 5-HT2c receptors in the ventral tegmental area. Neuroscience 146 4 (2007) 286-297
6. Cameron D.L., and Williams J.T. Cocaine inhibits GABA release in the VTA through endogenous 5-HT. J. Neurosci. 14 11 (1994) 6763-6767
7. Cheer J.F., Marsden C.A., Kendall D.A., and Mason R. Lack of response suppression follows repeated ventral tegmental cannabinoid administration: an in vitro electrophysiological study. Neuroscience 99 4 (2000) 661-667
8. Clifton P.G., Lee M.D., and Dourish C.T. Similarities in the action of Ro 60-0175, a 5-HT2C receptor agonist, and d-fenfluramine on feeding patterns in the rat. Psychopharmacology 152 3 (2000) 256-267
9. Cussac D., Newman-Tancredi A., Duqueyroix D., Pasteau V., and Millan M.J. Differential activation of Gq/11 and Gi3 proteins at 5-hydroxytryptamine2c receptors revealed by antibody capture assays: influence of receptor reserve and relationship to agonist-directed trafficking. Mol. Pharmacol. 62 3 (2002) 578-589
10. De Deurwaerdère P., Navailles S., Berg K.A., Clarke WilliamP., and Spampinato U. Constitutive activity of the serotonin2C receptor inhibits in vivo dopamine release in the rat striatum and nucleus accumbens. J. Neurosci. 24 13 (2004) 3235-3241
11. Di Giovanni G., De Deurwaerdère P., Di Mascio M., Di Matteo V., Esposito E., and Spampinato U. Selective blockade of serotonin2c/2b receptors enhances mesolimbic and mesostriatal dopaminergic function: a combined in vivo electrophysiological and microdialysis study. Neuroscience 91 2 (1999) 587-597
12. Di Matteo V., Cacchio M., Di Giulio C., and Esposito E. Role of serotonin(2C) receptors in the control of brain dopaminergic function. Pharmacol. Biochem. Behav. 71 4 (2002) 727-734
13. Di Matteo V., Di Giovanni G., Di Mascio M., and Esposito E. Biochemical and electrophysiological evidence that Ro 60-0175 inhibits mesolimbic dopaminergic function through serotonin2c receptors. Brain Res. 865 1 (2000) 85-90
14. Eberle-Wang K., Mikeladze Z., Uryu K., and Chesselet M.F. Pattern expression of the serotonin 2C receptor messenger RNA in the basal ganglia of adult rats. J. Comp. Neurol. 384 2 (1997) 233-247
15. Ferrari F., Ottani A., and Vivoli R. Learning impairment produced in rats by the cannabinoid HU 210 in a water-maze task. Pharmacol. Biochem. Behav. 64 (1999) 555-561
16. Fletcher P.J., Chintoh A.R., Sinyard J., and Higgins G.A. Injection of the 5-HT2c receptor agonist Ro60-0175 into the ventral tegmental area reduces cocaine-induced locomotor activity and cocaine self-administration. Neuropsychopharmacology 29 2 (2004) 308-318
17. French E.D., Dillon K., and Wu X. Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neuroreport 8 3 (1997) 649-652
18. Freund T.F., Kayona I., and Piomelli D. Role of endogenous cannabinoids in synaptic signaling. Physiol. Rev. 83 3 (2003) 1017-1066
19. Furnari F.B., Lin H., Huang H.S., and Cavenee W.K. Growth suppression of glioma cells by PTEN requires a functional phosphatase catalytic domain. Proc. Natl. Acad. Sci. U.S.A. 94 23 (1997) 12479-12484
20. Gainetdinov R.R., Premont R.T., Bohn L.M., Leftkowitz R.J., and Caron M.G. Desensitization of G protein-coupled receptors and neuronal functions. Ann. Rev. Neurosci. 27 (2004) 107-144
21. Gardner E.L. Endocannabinoid signaling system and brain reward: emphasis on dopamine. Pharmacol. Biochem. Behav. 81 (2005) 263-284
22. Gervais J., and Rouillard C. Dorsal raphe stimulation differentially modulates dopaminergic neurons in the ventral tegmental area and substantia nigra. Synapse 35 4 (2000) 281-291
23. Gessa G.L., Melis M., Muntoni A.L., and Diana M. Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors. Eur. J. Pharmacol. 341 1 (1998) 39-44
24. Grottick A.J., Corrigall W.A., and Higgins G.A. Activation of 5-HT2c receptors reduces the locomotor and rewarding effects of nicotine. Psychopharmacology 157 3 (2001) 292-298
25. Grottick A.J., Fletcher P.J., and Higgins G.A. Studies to investigate the role of 5-HT(2C) receptors on cocaine- and food-maintained behavior. J. Pharmacol. Exp. Ther. 295 3 (2000) 1183-1191
26. Herkenham M., Lynn A.B., Johnson M.R., Melvin L.S., de Costa B.R., and Rice K.C. Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiography study. J. Neurosci. 11 (1991) 563-583
27. Higgins G.A., and Fletcher P.J. Serotonin and drug reward: focus on 5-HT2C receptors. Eur. J. Pharmacol. 480 1-3 (2003) 151-162
28. Hill M.N., Froc D.J., Fox C.J., Gorzalka B.B., and Christie B.R. Prolonged cannabinoid treatment results in spatial working memory deficits and impaired long-term potentiation in the CA1 region of the hippocampus in vivo. Eur. J. Neurosci. 20 (2004) 859-863
29. Hoffman A.F., and Lupica C.R. Mechanisms of cannabinoid inhibition of GABA(A) synaptic transmission in the hippocampus. J. Neurosci. 20 7 (2000) 2470-2479
30. Hoffman A.F., and Lupica C.R. Direct actions of cannabinoids on synaptic transmission in the nucleus accumbens: a comparison with opioids. J. Neurophysiol. 85 1 (2001) 72-83
31. Hoffman A.F., Riegel A.C., and Lupica C.R. Functional localization of cannabinoid receptors and endogenous cannabinoid production in distinct neuron populations of the hippocampus. Eur. J. Neurosci. 18 3 (2003) 524-534
32. Ji S.P., Zhang Y., Van Cleemput J., Jiang W., Liao M., Li L., Wan Q., Backstrom J.R., and Zhang X. Disruption of PTEN coupling with 5-HT2C receptors suppresses behavioral responses induced by drugs of abuse. Nat. Med. 12 3 (2006) 324-329
33. Johnson S.W., and North R.A. Opioids excite dopamine neurons by hyperpolarization of local interneurons. J. Neurosci. 12 2 (1992) 483-488
34. Koob G.F., and Le Moal M. Drug abuse: hedonic homeostatic dysregulation. Science 278 5335 (1997) 52-58
35. Lachyankar M.B., Sultana N., Schonhoff C.M., Mitra P., Poluha W., Lambert S., Queensberry P.J., Litofsky N.S., Recht L.D., Nabi R., Miller S.J., Ohta S., Neel B.G., and Ross A.H. A role for nuclear PTEN in neuronal differentiation. J. Neurosci. 20 4 (2000) 1404-1413
36. Laviolette S.R., and van der Kooy D. The neurobiology of nicotine addiction: bridging the gap from molecule to behavior. Nat. Rev. Neurosci. 5 1 (2004) 55-65
37. Lee F.J., Xue S., Pei L., Vukusic B., Chery N., Wang Y., Wang Y.T., Niznik H.B., Yu X.M., and Liu F. Dual regulation of NMDA receptor functions by direct protein-protein interactions with the dopamine D1 receptor. Cell 111 2 (2002) 219-230
38. Lee S.P., O'Dowd B.F., and George S.R. Homo- and hetero-oligomerization of G protein-coupled receptors. Life Sci. 74 2-3 (2003) 173-180
39. Leslie N.R., and Downes C.P. PTEN function: how normal cells control it and tumour cells lose it. Biochem. J. 382 (2004) 1-11
40. Liu Q.S., Pu L., and Poo M.M. Repeated cocaine exposure in vivo facilitates LTP induction in midbrain dopamine neurons. Nature 437 7061 (2005) 1027-1031
41. Maehama T., and Dixon J.E. The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 273 22 (1998) 13375-13378
42. Müller C.P., and Carey R.J. Intracellular 5-HT2c receptor dephosphorylation: a new target for treating drug addiction. Trends Pharmacol. Sci. 27 9 (2006) 455-458
43. Myers M.P., Stolarov J.P., Eng C., Li J., Wang S.I., Wigler M.H., Parsons R., and Tonks N.K. P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc. Natl. Acad. Sci. U.S.A. 94 17 (1997) 9052-9057
44. Nestler E.J. Historical review: molecular and cellular mechanisms of opiate and cocaine addiction. Trends Pharmacol. Sci. 25 4 (2004) 210-218
45. Ning K., Pei L., Liao M., Liu B., Zhang Y., Jiang W., Mielke J.G., Li L., Chen Y., El-Hayek Y.H., Fehlings M.G., Zhang X., Liu F., Eubanks J., and Wan Q. Dual neuroprotective signaling mediated by downregulating two distinct phosphatase activities of PTEN. J. Neurosci. 24 16 (2004) 4052-4060
46. Pierucci M., Di Matteo V., and Esposito E. Stimulation of serotonin 2C receptors blocks the hyperactivation of midbrain dopamine neurons induced by nicotine administration. J. Pharmacol. Exp. Ther. 309 1 (2004) 109-118
47. Robbins T.W., and Everitt B.J. Drug addiction: bad habits add up. Nature 398 6728 (1999) 567-570
48. Robbins T.W., and Everitt B.J. Limbic-striatal memory systems and drug addiction. Neurobiol. Learn. Mem. 78 3 (2002) 625-636
49. Schlicker E., and Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol. Sci. 22 11 (2001) 565-572
50. Schwarze S.R., Ho A., Vocero-Akbani A., and Dowdy S.F. In vivo protein transduction: delivery of a biologically active protein into the mouse. Science 285 (1999) 1569-1572
51. Self D.W., Choi K.H., Simmons D., Walker J.R., and Smagula C.S. Extinction training regulates neuroadaptive responses to withdrawal from chronic cocaine self-administration. Learn. Mem. 11 5 (2004) 648-657
52. Stambolic V., Suzuki A., de la Pompa J.L., Brothers G.M., Mirtsos C., Sasaki T., Ruland J., Penninger J.M., Siderovski D.P., and Mak T.W. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell 95 1 (1998) 29-39
53. Stanford I.M., Kantaria M.A., Chahal H.S., Loucif K.C., and Wilson C.L. 5-hydroxytryptamine induced excitation and inhibition in the subthalamic nucleus: action at 5-HT2C, 5-HT4 and 5-HT1A receptors. Neuropharmacology 49 8 (2005) 1228-1234
54. Szabo B., Siemas S., and Wallmichrath I. Inhibition of GABAergic neurotransmission in the ventral tegmental area by cannabinoids. Eur. J. Neurosci. 15 12 (2002) 2057-2061
55. Wang J.Q., Fibuch E.E., and Mao L. Regulation of mitogen-activated protein kinases by glutamate receptors. J. Neurochem. 100 1 (2007) 1-11
56. Wang Y., Cheng A., and Mattson M.P. The PTEN phosphatase is essential for long-term depression of hippocampus synapses. Neuromolecular Med. 8 3 (2006) 329-336
57. Weng L.P., Brown J.L., and Eng C. PTEN coordinates G(1) arrest by down-regulating cyclin D1 via its protein phosphatase activity and up-regulating p27 via its lipid phosphatase activity in a breast cancer model. Hum. Mol. Genet. 10 6 (2001) 599-604
58. Westphal R.S., Backstrom J.R., and Sanders-Bush E. Increase basal phosphorylation of the constitutively active serotonin 2C receptor accompanies agonist-mediated desensitization. Mol. Pharmacol. 48 2 (1995) 200-205
59. Wong T.P., Howland J.G., Robillard J.M., Ge Y., Yu W., Titterness A.K., Brebner K., Liu L., Weinberg J., Christie B.R., Phillips A.G., and Wang Y.T. Hippocampal long-term depression mediates acute stress-induced spatial memory retrieval impairment. Proc. Natl. Acad. Sci. U.S.A. 104 27 (2007) 11471-11476
60. Wood M.D. Therapeutic potential of 5-HT2C receptor antagonists in the treatment of anxiety disorders. Curr. Drug Targets CNS Neurol. Disord. 2 (2003) 383-387
61. Wu X., and French E.D. Effects of chronic delta9-tetrahydrocannabinol on rat midbrain dopamine neurons: an electrophysiological assessment. Neuropharmacology 39 3 (2000) 391-398
62. Xu L., Anwyl R., and Rowan M.J. Behavioural stress facilitates the induction of long-term depression in the hippocampus. Nature 387 6632 (1997) 497-500